Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus

Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus

Abstract Hepatitis E virus (HEV) infection is a major cause of acute viral hepatitis worldwide. The efficacy and safety of the HEV239 vaccine have been validated, with protection lasting at least 10 years. This study extended the phase 3 trial of HEV239 (NCT01014845), presenting data on the durabili...

Full description

Saved in:
Bibliographic Details
Main Authors: Kongxin Zhu, Mengjun Liao, Lu Chen, Jiaoxi Lu, Xingcheng Huang, Chunlan Zhuang, Yingying Su, Shoujie Huang, Ting Wu, Jun Zhang, Ningshao Xia
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-024-01041-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items